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Abstract.  L-selectin expressed by granulocytes, lym- 
phocytes, and monocytes is responsible for initial leu- 
kocyte attachment to inflamed endothelium and high 
endothelial venules of peripheral  lymph nodes. After 
leukocyte activation in vitro, L-selectin is rapidly shed 
from the cell surface.  In this study, shed L-selectin 
(sL-selectin) from both lymphocytes and neutrophils 
was demonstrated to be present in high levels in hu- 
man plasma by Western blot analysis and using a quan- 
titative ELISA.  In serum from normal human blood 
donors, a mean sL-selectin level of 1.6  ___ 0.8 #g/ml 
(n  =  63) was found by ELISA. In addition,  semi- 
purified sL-selectin from plasma inhibited L-selectin- 
specific attachment of lymphocytes to cytokine- 
activated endothelium in a dose-dependent manner. 
L-selectin-dependent leukocyte attachment was com- 
pletely inhibited at sL-selectin concentrations of 8-15 
/zg/ml,  while physiological concentrations of sL- 
selectin caused a  small but consistent inhibition of 
lymphocyte attachment,  sL-selectin in plasma also in- 
hibited anti-L-selectin mAb (2-5 #g/ml) binding to 
the surface of leukocytes. Interestingly,  one epitope 
present within the EGF-like domain of L-selectin was 
lost in sL-selectin,  suggesting a  conformational change 
in the structure of the receptor after shedding.  The 
presence of serum sL-selectin with functional activity 
indicates a potential role for sL-selectin in the regula- 
tion of leukocyte attachment to endothelium. 
T 
HE ability of leukocytes to leave the circulation  and 
to migrate into tissues is a critical  feature of the im- 
mune  response.  Several  adhesion  molecules are in- 
volved in  the  process of adhesion  and  transmigration  of 
leukocytes through  vascular endothelium  at sites of inflam- 
mation (45). One molecule responsible for the initial attach- 
ment of leukocytes to endothelium  is L-selectin (Leukocyte 
Adhesion  Molecule-1  [LAM-1]  t MEL-14)  (24,  30, 43, 44). 
L-selectin is a member of the selectin  family  of adhesion 
molecules (3,  11,  27,  36,  37,  49) that  includes  E-selectin 
(Endothelial-Leukocyte  Adhesion Molecule-1 [ELAM-1]) (1, 
2, 31, 32) and CD62 (P-selectin,  PADGEM, GMP-140) (13, 
18, 25, 26). The selectins are derived from evolutionarily re- 
lated  genes (7,  9,  18,  33,  52),  and are characterized  by a 
NH2-terminal,  Ca-dependent  lectin  domain,  an epider- 
mal growth factor (EGF)-like domain followed by multi- 
ple short consensus repeat (SCR) domains, a transmem- 
brane region,  and a cytoplasmic tail. 
L-selectin is expressed on the surface of most leukocytes, 
including lymphocytes,  neutrophils,  monocytes, eosinophils, 
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hematopoietic progenitor cells,  and immature  thymocytes 
(14, 51). L-selectin is a highly glycosylated protein of 95-105 
kD  on  neutrophils  and  74 kD on lymphocytes (14,  50). 
Human and mouse L-selectin mediate the binding  of lym- 
phocytes to high  endothelial  venules (HEV) of peripheral 
lymph nodes through  interactions  with a constitutively  ex- 
pressed ligand (16, 23, 40, 46, 51), and are also involved in 
lymphocyte, neutrophil,  and monocyte attachment to endo- 
thelium at sites of inflammation  (15, 20, 29, 39, 43, 44, 54). 
In vitro, endothelial  cell surface expression of the L-selectin 
ligand(s)  is induced only after exposure of the endothelial 
cells to inflammatory  cytoldnes, and the endothelial  ligand 
shares many functional features with the L-selectin ligand(s) 
expressed by HEV  (39,  43).  Sulfated  carbohydrates  and 
mAbs which bind to the lectin domain of L-selectin, inhibit 
L-selectin-specific adhesion  (16, 21, 43, 47, 56, 57). Thus, 
the lectin domain of L-selectin seems to mediate ligand bind- 
ing, while the EGF-like and SCR domains may somehow 
regulate the affinity of this interaction  (21, 38, 41, 42, 55). 
A unique feature of L-selectin is that it is shed from the 
cell surface after cellular activation in vitro (14, 19, 22, 23, 
40). It has been proposed, at least in the mouse model, that 
shedding of MEL-14 from leukocytes might be necessary to 
enable leukocytes to transmigrate  through endothelium into 
sites of inflammation  in vivo (20, 22). This would provide 
a rapid means for the regulation  of leukocyte adhesion and 
deadhesion to endothelium.  Although  the subsequent fate 
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molecule  is  not known,  elegant  studies  by Woodruff and 
colleagues have previously demonstrated the presence of a 
soluble factor in rat thoracic duct lymph capable of inhibit- 
ing  lymphocyte binding  to  HEV  (4).  Furthermore,  they 
demonstrated that this factor was antigenically related to a 
structure(s) present on lymphocytes and speculated that this 
cell-surface molecule might play a role in adherence of lym- 
phocytes to HEV of lymph nodes (4, 5, 6). 
A number of surface molecules present on cells of various 
lineages are now known to be shed and thereby released into 
the extracellular milieu (48). These include the receptors for 
interleukin-1,  intedeukin-2  (CD25), transferrin  (CD71), in- 
sulin, growth hormone, tumor necrosis factor (34), colony- 
stimulation factor-1  (10), and nerve growth factor (8), as well 
as CD8 and CD14. These proteins are quite diverse in struc- 
ture and amino acid sequence and have no unifying func- 
tional characteristics that are currently appreciated. In most 
cases,  proteases  cleave the  receptor  near  the  membrane, 
releasing a nearly intact extracellular domain with ligand- 
binding activity (8, 10, 22, 40). Thus, receptor function may 
not only be regulated by proteolytic cleavage of the receptor 
from the cell surface, but also by the presence of shed recep- 
tor  in  the  extracellular  environment.  The  present  study 
shows that sL-selectin from neutrophils and lymphocytes is 
found in plasma at high levels and that it may retain func- 
tional activity. Since sL-selectin inhibited L-selectin-medi- 
ated adhesion in vitro, it may modulate leukocyte binding to 
endothelium in vivo. 
Materials and Methods 
Antibodies 
L-selectin directed mAbs were the anti-LAM1-3, -4, -6, -7, -8, -10, -11, and 
-12 mAbs directed against epitopes within the lectin domain, anti-LAMl-1, 
-5 and -15 reactive with epitopes within the EGF-like domain and anti- 
LAMl-14 which reacts with the SCR regions of L-selectin,  all of the IgGl 
isotype (42). The anti-L-selectin mAbs were purified by salt fractionation 
followed by anion exchange chromatography,  with the mAb concentration 
determined by  light absorption.  The anti-LAM1-3 mAb was  bound to 
CNBr-activated  Sepharose  4B (Pharmacia LKB Biotechnology  Inc., Pis- 
caraway, N J) at 2.5  nag of mAb bound per  1 ml of beads (anti-LAM- 
Sepbarose)  using the methods of the manufacturer. 
Isolation of  Blood Mononuclear Cells 
Heparinized blood was obtained according to protocols approved by the Hu- 
man Protection Committee of Dana-Farber Cancer Institute, Boston, MA. 
Mononuclear cells were isolated by Ficoll Hypaque density gradient cen- 
trifugation.  Cells were immediately resuspended  in RPMI  1640  (Gibco- 
BRL, Gaithersburg, MD) containing 10% FCS and kept at 4~  until use. 
In most instances, these cells will be referred  to as lymphocytes  since 
85-95 % of the cell population was lymphocytes as determined by morphol- 
ogy (Wright's stain) and flow cytometry analysis.  Neutrophils were purified 
by centrifugation on a cushion of Mono-Poly Resolving  Medium (Flow 
Laboratories, Inc., McLean, VA) followed by lysis of the red cells with ice- 
cold hypotonic 0.2%  (wt/vol)  NaCI  solution.  Neutrophils were  finally 
resuspended in HBSS containing 5 % FCS (Sigma Chemical Co., St. Louis, 
MO).  When  sL-selectin  was  obtained  for  Western  blot  analysis,  the 
mononuclear cells were  first  incubated in plastic dishes for 30 min in 
RPMI/10% FCS at 37~  to remove adherent monocytes.  Nonadherent cells 
retained surface L-selectin and were predominantly lymphocytes  (•99  %). 
Cell Cultures 
Lymphocytes  were cultured  in 24-well plates (Costar Corp., Cambridge, 
MA) at 106/ml in RPMI  1640 medium containing 10% FCS,  2% L-glu- 
tamine, penicillin, and streptomycin.  The cells were cultured with PMA 
(100 ng/ml) for 60 min before the culture medium was harvested and tested 
for sL-selectin by ELISA.  Neutrophils were incubated in polypropylene 
tubes at 8  ￿  106 cells/ml for 60 rain at 37~  either in HBSS/5%  FCS 
medium alone or containing granulocyte/monocyte-colony  stimulating fac- 
tor (25 ng/ml; a gift from Drs.  Steven Clark and Gordon Wong, Genetics 
Institute,  Cambridge,  MA),  monocyte-colony  stimulating  factor  (100 
ng/ml; Genetics Institute),  tumor necrosis factor-c~ (TNF-c~; 100 U/ml; 
Genzyme Corp., Cambridge,  MA), lipopolysaccharide  (I /zg/ml; Esche- 
richia  coli  011:IM; Sigma  Chemical  Co.),  formyl-methionyl-leucyl- 
phenylalanine  (10  -s M; Sigma Chemical Co.),  interferon- 7  (1,000 U/ml; 
Genzyme Corp.), or interleukin-1/3 (10 U/ml; Genzyme Corp.).  After cul- 
ture,  the supernatant fluid was tested for the presence of sL-selectin by 
ELISA. The human erythroleukemia cell line, K562,  was transfected  with 
the pLAM-1 eDNA as previously  described (51) and will be called IO62- 
LAM throughout. These cells were cultured in RPMI 1640/10% FCS and 
were kept at cell numbers between 0.2 and 1 ￿  106 ceUs/ml. All cells were 
incubated at 37~  in 5% CO2 with 100% humidity. 
Indirect Immunofluorescence Analysis 
Indirect immunofluorescence  analysis was carried out after washing  the 
cells three times.  Cells (1  x  106 cells) were resuspended  in 100/zl of me- 
dia containing various concentrations of the indicated mAb, and incubated 
for 60  rain at 4"C.  After washing,  the cells  were  treated with FITC- 
conjugated goat anti-mouse Ig antibodies (Southern Biotechnology  Associ- 
ates, Birmingham, AL) for 20 min at 4~  The cells were washed, and fixed 
(1% paraformaldehyde  in PBS),  and single color fluorescence  was deter- 
mined on a flow cytometer (ELITEr'; Coulter Immunology,  Hialeah, FL). 
10,000 cells were analyzed for each sample and the relative mean fluores- 
cence intensity  of L-selectin + cells was determined on a linear scale. 
In  some  experiments,  cells  were  stained in the presence of human 
plasma, sL-selectin was precleared from an aliquot of the same plasma by 
immunoprecipitation with anti-LAM-Sepharose (I ml of beads per 4 ml of 
plasma). The efficiency of the immunoprecipitations was tested by ELISA 
(<20 ng/ml).  Lymphocytes  (I  x  106) were resuspended either in 100/zl of 
plasma  or  precleared  plasma  containing various  concentrations of the 
purified mAb (added  1:100) as indicated.  The cells were  washed  twice, 
stained, and analyzed as above. 
sL-selectin Purification 
sL-selectin was semipurified  from plasma obtained from heparinized hu- 
man blood.  Plasma was salt-fractionated  with Na2SO4 (18% wt/vol) before 
the sL-selectin containing supernatant fraction was dialyzed against 0.02 M 
Tris buffer, pH 8.0, 0.5 M NaCI.  The sL-selectin preparation was further 
purified by affinity column chromatography using anfi-LAM-Sepharose. 
sL-selectin was eluted from the column with 0.1 M Na a~etate buffer, pH 
3.5, 0.15 M NaC1, and the low pH of the eluate was immediately raised by 
the addition of 2.0 M Tris buffer, pH 9.0. The pooled fractions of the eluate 
peak were concentrated and transferred into PBS by ultrafiltration.  The con- 
centration of sL-selectin was determined by ELISA and subsequently  ad- 
justed to ,~15 #g/ml in PBS. At this sL-selectin concentration, the total pro- 
tein concentration of the samples varied between 130 and 220/~g/ml, and 
sL-selectin represented "~6-10 % of total protein. In general, this procedure 
gave a 2,200-3,700-fold enrichment for sL-selectin.  For use in lymphocyte- 
endothelial adhesion assays, semipurified  sL-selectin was transferred into 
RPMI 1640/10% FCS by further ultraliltration. 
Western Blot Analysis 
sL-selectin was semipurified  from plasma as described above and further 
purified by immunoprecipitation using anti-LAM-Sepharose with repeated 
washing  of the beads in alternating high salt (0.5  M  NaCI,  0.2%  Na- 
deoxycholate)  and low salt (0.125 M NaCI, 0.05 % Na-deoxycholate)  RIPA 
buffer (100 mM Tris, pH 8.0, 1% [vol/vol] Triton X-100, 10 mM EDTA, 
10 mM EGTA,  I0 mM NaF, 1 mg/ml BSA). Proteins were elu~,xl from the 
beads with 0.1 M acetate buffer, pH 3.5, 0.15 M NaC1. Supernatant fluid 
from PMA-stimulated cells was also analyzed.  Cells (1  x  107/ml), includ- 
ing neutrophils (10 ng/ml PMA in RPMI 1640 for 10 rain at 37~  lympho- 
cytes (10 ng/ml PMA in RPMI 1640 for 25 rain at 37~  and K562-LAM 
transfectants  (100 ng/ml PMA in PBS for 120 rain at 37~  were induced 
to  shed essentially all  detectable cell  surface  L-selectin,  before  being 
pelleted by centrifugation (4~  400 g, 10 min). The supernatant fluid was 
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MA). Protein samples (100 ~1) were applied to a 7.5 % SDS-polyacrylamide 
gel, electrophoresed, and blotted onto nitrocellulose.  Western blot analysis 
was  performed using the anti-LAMl-14 mAb (ascites,  1:2,000)  as the 
antigen-detecting  antibody. The blot was developed using alkaline phospha- 
tase conjugated goat anti-mouse IgG1 antibody (Southern Biotechnology 
Associates)  and NBT/BCIP as substrate (Promega Corp., Madison, WI). 
In preliminary experiments, the anti-LAMl-14 mAb was the most sensitive 
of the 12 anti-L-selectin mAbs tested, of which anti-LAM1-3,  -4, -8, -10, 
and -15 mAb were also found to give positive staining. 
Endothelial-Leukocyte Attachment Assay 
Lymphocyte  adhesion to cytoldne-activated endothelium under nonstatic 
conditions was  determined in a  test system  adapted from the Stamper/ 
Woodruff assay for frozen tissue sections (46) exactly as described (43). 
Briefly,  human umbilical vein endothelial cells (HUVEC) were isolated 
from cord veins, and grown in M199 medium supplemented with 10% FCS, 
endothelial cell growth factor (50 t~g/ral, Biomedical  Technologies,  Inc., 
Stoughton, MA) and porcine intestinal  beparin (50 mg/ml; Sigma Chemical 
Co.) as described (43). Endothelial cells were grown to confluence on gela- 
tin (0.1%)-coated  glass slides and stimulated with TNF-a (100 U/ml) at 
37~  for the times indicated. The monolayers  were carefully  washed and 
incubated at 4~  for 15 rain with 75/zl of RPMI/10% FCS alone or contain- 
ing semipurified sL-selectin.  As a control, in some instances media contain- 
ing semipurified  sL-selectin were precleared by immunoprecipitation with 
anti-LAM-Sepharose. Without further washing,  5  ￿  106 lymphoeytes  in 
75 t21 of the respective media were added. After 20 rain of incubation at 
4~  with rotation at 64 rpm, the slides were fixed overnight in glutaralde- 
hyde (1% [vol/vol] in PBS; Polysciences, Warrington, PA), and stained with 
hematoxylin. The number of adherent leukooytes was determined by count- 
ing six microscopic fields (0.09 mm2/field) and the results were expressed 
as means +  SD. 
Production of the L-selectin and IgG Chimera cDNA 
and Protein 
Generation of the L-selectin and IgG chimeric cDNA will be described in 
detail elsewhere (44a). Basically, the 1400-bp BanlI fragment from a eDNA 
encoding the CH1 through CH3 domains of the human IgGl constant re- 
gion was  inserted at a  BanlI site introduced into pLAM-1  cDNA (49) 
(amino acid number 370 in the membrane proximal region of the mature 
protein) by oligonucleotide  directed mutngenesis.  The recombinant DNA 
was sequenced and the conservation of L-selectin and IgG~ restriction sites 
in the pLAM-IgG DNA was contirmed by restriction mapping.  The LAM- 
IgG DNA was subeloned into the AprM8 expression vector (provided by 
Dr. Lloyd Klickstein,  Center for Blood Research, Boston, MA) and used 
to transiently transfect COS cells by the DEAE dextran method. The trans- 
fected COS cells were cultured in AIM-V serum-free media (Gibeo-BRL) 
and the supernatant fluid containing the chimeric LAM-IgG fusion protein 
was harvested after 3 d. 
sL-selectin ELISA 
The ELISA used to quantitate sL-selectin levels in biological fluids will be 
described in detail elsewhere (44a). Briefly, wells of microtiter plates (96 
welt,  flat bottom, E.I.A./R.I.A.  plate,  Costar,  Cambridge,  MA) were 
coated with anti-L-selectin rnAb as indicated. After washing with TBS, the 
wells were blocked with 2% BSA and 1% gelatin in TBS. The wells were 
washed, and the test samples were added to triplicate wells. Each assay in- 
cluded the titration of a previously quantified plasma sample that was used 
to generate a standard curve. After washing, the plates were incubated with 
biotinylated anti-LAM1-3 mAb (1 /~g/ml) for 60 rain at 20~  The wells 
were washed, and avidin-HRP (0.1/zg/ml,  Pierce Chemical Co., Rockford, 
IL) was added for 30 rain at 20~  Again, the plates were washed and finally 
developed using o-phenylenediamine (0.125%  wt/vol,  Sigma Chemical 
Co.) as a substrate in 0.1 M citrate buffer, pH 4.5, in the presence of H202. 
The OD of the reaction mixture was quantitated using an ELISA-reader 
(Vmax kinetic microplate reader; Molecular Devices,  Menlo Park, CA). 
Results were obtained when the OD for the well containing the highest con- 
centration of standard plasma was ,00.8 at 495 nm. The relative concentra- 
lion of sL-selectin in individual samples was calculated by comparing the 
mean OD obtained for triplicate wells with a semilog standard curve of 
titrated plasma using linear regression analysis (r ~  0.97). 
The amount of sL-selectin present in the standard plasma was quantitated 
in two ways. First, K562-LAM-1  cells ('011 liters of cultured ceils,  "01.1 
x  10  l~ cells) were resuspended in PBS (1  x  107 cells/ml) and were stimu- 
lated with PMA (100 ng/ml) for 2 h at 37~  The supernatant fluid was 
collected, concentrated by ultrafiltration, and affinity purified by column 
chromatography using anti-LAM-Sepharose as described above. The semi- 
purified sample was electrophoresed on a  10% SDS-polyacrylamide gel 
that was subsequently stained by Coomassie blue to reveal a prominent 71- 
kD band and additional bands of eul80,  57, 47, and 22 kD. The gel was 
scanned using a Hewlett Packard Desk Scanner and the density of the 7 l-kD 
band was quantitated against a standard curve generated with BSA using 
the Enlmnce  TM  program (Microsystems,  Des  Moines,  IA) on an Apple 
Macintosh Ilcx computer.  The concentration of sL-selectin in the standard 
plasma was calculated to be "01.3 t~g/ml by comparing the signal from semi- 
purified sL-selectin to the L-selectin-ELISA titration curve of standard 
plasma with linear regression analysis. The detection limit of the L-selectin- 
ELISA was determined to be ;~5 ng/ml. In a second set of experiments, COS 
cells were grown in serum-free medium after transient transfection with the 
LAM-IgG chimera eDNA. Supernatant fluid was collected from the cells 
and  run over a  Protein A-Sepharose (Pharmacia LKB  Biotechnology) 
affinity chromatography column and the fusion protein was duted from the 
column by high salt-tow pH buffer. The purified fusion protein was quanti- 
tated after SDS-PAGE analysis by comparison of the stained protein band 
with a  standard curve of BSA.  From this analysis,  it appeared that OD 
values for standard plasma would be equivalent to "01.9 t~g/ml of LAM-IgG 
fusion protein. Since the dimeric nature of the fusion protein might double 
the intensity of staining in our sandwich ELISA, the amount of sL-setectin 
in the standard plasma may be half the value of ,ol.9/~g/mt. 
Statistics 
Statistical  analysis  used the paired or unpaired t test appropriately. 
Results 
Detection of  sL-selectin in Plasma by Western 
Blot Analysis 
In vitro, leukocytes and L-selectin cDNA-transfected cells 
shed L-selectin from the cell surface that can be detected in 
the culture supernatant fluid. To determine whether this pro- 
cess  also  occurs  in  vivo,  the  anti-LAM1-3  mAb,  which 
identifies an epitope within the lectin domain, was used to 
immunoprecipitate reactive materials  from normal human 
plasma.  The precipitated materials were then analyzed by 
SDS-PAGE, transferred to nitrocellulose, and the presence 
of a  soluble form of L-selectin was visualized by Western 
blot analysis using the anti-LAMl-14 mAh that hinds to a 
L-selectin epitope located within the SCR region. Two pre- 
dominant isoforms of sL-selectin were observed, a '~62-kD 
isoform and a 75-100-kD isoform (Fig.  1). Analysis of the 
culture supernatant fluid from PMA-stirnulated lymphocytes, 
neutrophils,  and  K562  cells  transfected  with  L-selectin 
eDNA  (K562-LAM)  revealed different,  cell-specific iso- 
forms of sL-selectin (Fig. 1). Neutrophils shed a 75-100-kD 
isoform of sL-selectin that traveled as a broad band with an 
ill-defined upper border most likely due to heavy glycosyla- 
tion (33). Lymphocytes  generated a 62-kD isoform and K562- 
LAM cells shed a 71-kD isoform of sL-selectin. No specific 
proteins were isolated from the supernatant fluid of untrans- 
fected K562 cells using the above assays, and preclearing the 
plasma  or  supernatant  fluid  with  the  anti-LAM1-3  mAb 
eliminated subsequent Western blot results (data not shown). 
Therefore, it is likely that the two predominant isoforms of 
sL-selectin identified in plasma derived from both lympho- 
cytes and neutrophils.  Furthermore,  sL-selectin in serum 
contained the lectin, EGF, and SCR domains as it was visu- 
alized in these experiments using mAb reactive with the lec- 
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sL-selectin detected by West- 
ern blot analysis.  Plasma from 
a normal donor was salt frac- 
tionated,  purified  by affinity 
chromatography,  and  immu- 
noprecipitation  using  anti- 
LAM1-3  mAb  bound  to 
Sepharose  beads.  Lympho- 
cytes, neutrophils,  and K562- 
LAM cells (1  x  107/ml) were 
incubated  with PMA, and the 
culture supernatant fluids were 
isolated and concentrated ten- 
fold  by  ultratiltration.  The 
harvested  materials  were ana- 
lyzed by SDS-PAGE  (7.5%), 
blotted  onto  nitrocellulose, 
and  stained  with  the  anti- 
LAMI-14  mAb  for  Western 
blot analysis. 
tin  (anti-LAM1-3) and SCR (anti-LAMl-14)  domains,  but 
the relative molecular mass of sL-selectin is smaller than that 
for  L-selectin  isolated  from detergent  solubilized  cells  as 
previously described  (27, 40). 
Quantitation of  sL-selectin in Plasma and Serum 
by ELISA 
The amount of sL-selectin found in human plasma was quan- 
titated with a sandwich ELISA using the anti-LAM1-5 mAb 
as a capture antibody and biotinylated anti-LAM1-3 mAb as 
a  detecting  antibody.  This  specific  combination  of mAb 
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Figure 2. Quantitation of sL-selectin levels in sera of normal indi- 
viduals.  Serum was examined for sL-selectin by a sandwich ELISA 
using the anti-LAM1-5 mAb as catching  antibody.  Biotinylated 
anti-LAM1-3 mAb was used as detecting  antibody,  with avidin- 
HRP and o-phenylenediamine used as substrate for visualization  of 
anti-LAM1-3 mAb binding.  Standardization  of the ELISA is de- 
scribed in detail in Materials and Methods.  Values represent  the 
mean values  +  SD obtained in triplicate  determinations  for each 
sample. 
provided the highest level of sensitivity so that "~5 ng of sL- 
selectin could be easily detected. The level of sL-selectin de- 
termined by ELISA in the sera of a population of healthy nor- 
mal blood donors was found to be 1.6  5:0.8 #g/ml, n  =  63 
(Fig. 2). In some donors, sL-selectin levels were simultane- 
ously quantitated  in plasma and serum with similar results 
obtained (1.9  5:1.0 #g/ml, n  =  18).  It is unlikely that sL- 
selectin in plasma or serum might still be membrane bound, 
as the same levels of sL-selectin were found in serum and 
plasma before and after ultracentrifugation,  sL-selectin was 
stable in whole blood left to stand at 20~  before separation 
of serum or plasma for at least 24 h.  Storage of serum or 
plasma at 4~  for up to three months in the presence of azide 
or repeated thawing and freezing (up to  10 times)  did not 
affect the ability to detect sL-selectin in serum. In conclusion, 
it appears that sL-selectin is stable and present at relatively 
high levels in human plasma and  serum. 
Quantitation of sL-selectin in Supernatants of 
Activated Leukocytes 
Stimulation  or  the  culturing  of  leukocytes  has  been  as- 
sociated with shedding  of L-selectin from the cell surface. 
Therefore, experiments were carried out to determine if sL- 
selectin  accumulated  in culture  supernatant  fluid.  Culture 
supernatant fluid obtained from an erythroleukemia cell line 
transfected with the pLAM-1 eDNA (K562-LAM) was found 
to contain detectable sL-selectin, in contrast to supernatant 
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Figure 3. Neutrophils  and lymphocytes shed L-selectin after activa- 
tion.  Culture  supematant  fluid  from pLAM-1 cDNA-transfected 
K562 cells or untransfected cells (Control, []) were analyzed.  Neu- 
trophils  and lymphocytes (8  x  106/ml) were incubated  in 24-well 
flat-bottom culture plates for 1 h at 37~  in the presence of  medium 
alone (culture) or medium containing monocyte-colony  stimulating 
factor (M-CSF), granulocyte/monocyte-colony stimulating  factor 
(GM-CSF), formyl-methionyl-leucyl-phenylalanine  (FLMP), TNF 
or lipopolysaccharide (LPS). Culture media were harvested,  cen- 
trifuged, and supematant fluids were tested for sL-selectin by ELISA. 
Culture medium alone served as controls (~). Values represent the 
mean OD values  +  SD obtained in triplicate  determinations  for 
each sample. These results are representative  of 12 K652-LAM ex- 
periments,  two neutrophil  experiments,  and three lymphocyte ex- 
periments. 
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density (Fig. 3 a). Similarly, medium from freshly isolated 
neutrophils cultured at 37~  for 60 min also contained de- 
tectable sL-selectin (Fig. 3 b). Incubation of the neutrophils 
with stimuli that do not affect cell surface L-selectin expres- 
sion,  granulocyte-colony stimulating  factor, interleukin  1, 
monocyte-colony stimulating factor, interleukin 6, interferon 
% and interleuldn 4, did not induce an increase in sL-selectin 
in these experiments. However, stimulation with formylated 
methionine-leucine-phenylalanine, lipopolysaccharide, gran- 
ulocyte/monocyte-colony stimulating  factor,  interleukin 8, 
and tumor necrosis factor (TNF) induced L-selectin shed- 
ding corresponding to their potency to stimulate cell surface 
shedding (Fig. 3 b and data not shown). Culturing lympho- 
cytes for 60 rain at 37~  caused some shedding of  L-selectin, 
which was greatly enhanced by PMA treatment (Fig. 3 c). 
In similar experiments, quantitation of the amount of sL- 
selectin found in the supernatant fluid after activation of neu- 
trophils and lymphocytes (1  x  l07 cells/ml) varied between 
~10-30 ng/ml. However, PMA-activation in PBS oflympho- 
cytes for >25 min, and neutrophils for >10 min, resulted in 
the gradual degradation of sL-selectin. Degradation was not 
observed in the supernatant from K562-LAM cells, where 
sL-selectin was consistently found at concentrations of 22 5= 
6 ng/ml (1.7 5: 0.5% of standard plasma; n =  14). In experi- 
ments not shown,  elevated levels of sL-selectin were also 
detected  in  the  culture  supernatant  fluid of lymphocytes 
cultured  with  phytohemagglutinin,  concanavalin  A,  and 
pokeweed mitogen for 3-6 d at 37~  These mitogens are 
known to cause cell surface loss of  L-selectin (51). Thus, loss 
of L-selectin from the cell surface directly correlates with an 
increase of sL-selectin in the culture medium. 
Inhibition of  Lymphocyte Binding to Activated 
Endothelium by sL-selectin 
sL-selectin was  semipurified from plasma by salt fraction- 
ation  followed by affinity chromatography with  the  anti- 
LAM1-3 mAb. The column eluate was concentrated, and the 
level of sL-selectin present was quantitated by ELISA and 
adjusted to ~15 t~g/ml (6-10% of total eluate protein), sL- 
selectin,  at  different concentrations,  in  RPMI  1640/10% 
FCS was incubated (15 rain, 4~  with cytokine-activated 
endothelial cells before examining lymphocyte attachment to 
endothelium through L-selectin. While sL-selectin at physi- 
ological  concentrations  caused  only  partial  inhibition  of 
lymphocyte attachment (32.1  +  15.9%,  n  =  10),  it was 
found  to  inhibit  most  L-selectin-dependent  lymphocyte 
binding at concentrations of 8/~g/ml (52-100 %) and caused 
almost total  inhibition of L-selectin-mediated binding  at 
12-15 #g/ml  (93-100%;  Fig.  4  depicts a  typical dose re- 
sponse curve). Lymphocyte binding mediated by L-selectin 
was calculated as the difference between total binding at any 
given concentration of sL-selectin and lymphocyte binding 
found in the presence of anti-LAM1-3 mAb, which blocks 
all  L-selectin  mediated  adhesion  (43).  Importantly,  sL- 
selectin at 15 pg/ml caused no additional inhibition of lym- 
phocyte binding  beyond that  obtained  with  anti-LAM1-3 
mAb alone. When the sL-selectin samples were precleared 
with the anti-LAMl-15 mAb (which does not block L-selec- 
tin adhesion) before the assays, the preparation was not able 
to inhibit lymphocyte attachment,  demonstrating that sL- 
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Figure 4. Inhibition of lymphocyte binding to activated endothe- 
lium  by sL-selectin.  Confluent monolayers of endothelial cells 
grown on slides were activated with TNF (100 U/ml) for 3 h, fol- 
lowed by incubation (4~  15 min) with medium containing various 
concentrations of sL-selectin (in 75 #1) that was semipurified from 
plasma and resuspended in RPMI 1640/10% FCS. Blood lympho- 
cytes (5  x  106) in 75/~1 of medium (,) or medium containing 
anti-LAM1-3 mAb (15 pg,  o) were layered onto the slides for 20 
min at 4~  with rotation at 64 rpm. Attachment of lymphocytes in 
the presence of anti-LAM1-3 mAb indicates L-selectin-indepen- 
dent binding. Results obtained with a portion of the sL-selectin 
preparation (equivalent  to that used at 15.7/~g/ml)  that was first pre- 
cleared with the anti-LAMl-15 mAb are shown as open symbols. 
Values represent the means + SD of six counted fields, and are typ- 
ical for three experiments. 
selectin mediated the inhibition (Fig. 4).  Thus,  it appears 
that sL-selectin is capable of inhibiting L-selectin-specific 
lymphocyte adhesion to endothelium by binding to its puta- 
tive endothelial ligand. 
The inhibitory capacity of sL-selectin at normal physio- 
logical concentrations (1.5 #g/ml) was further evaluated to 
determine if it could alter the interaction of lymphocytes with 
endothelium.  Endothelium  was  activated with  TNF  (100 
U/ml) for different periods of time to induce the L-selectin 
ligand  in  a  manner similar to what might happen during 
the initiation of  an inflammatory response. During the course 
of induction of the L-selectin ligand,  sL-selectin treatment 
of the endothelium caused a consistent, but small, inhibition 
of L-selectin-dependent lymphocyte attachment (30% at 2 h, 
43 % at 3 h, 41% at 4 h, 15 % at 5 h, and 2 % at 6 h) (Fig. 5). 
Again, the combination of sL-selectin with the anti-LAM1-3 
mAb did not cause a greater inhibition than that observed 
with the mAb alone. Thus, during the development of an in- 
flammatory response, it is likely that sL-selectin will be able 
to alter the course of leukocyte attachment, although the in- 
fluence appears to be small in this in vitro assay. 
sL-selectin in Serum Blocks Anti-L-selectin 
mAb Binding 
The presence of circulating sL-selectin was further verified 
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Figure 5. Inhibition of lymphocyte-endothelial  binding by physio- 
logical levels of sL-selectin.  Confluent monolayers of endothelial 
cells grown on slides were activated with TNF (100 U/ml) for vari- 
ous time periods as indicated. The slides were then washed and in- 
cubated (4~  15 rain) with 75 td of medium alone (circles) or me- 
dium containing  1.5/~g/ml sL-selectin that was semipurified from 
plasma (squares). Blood lymphocytes (5  x  106) in 75/zl of me- 
dium (I, e) or medium containing the anti-LAM1-3 mAb ([], o; 
15/~g) were layered onto the slides for 20 min at 4~  with rotation 
at 64 rpm. Attachment of lymphocytes in the presence  of anti- 
LAM1-3 mAb indicates  L-selectin-independent  binding.  Values 
represent the means 5- SD of six counted fields, and are typical for 
three experiments. Time points designated by asterisks indicate sta- 
tistically significant differences (P <  0.005) between attachment 
with or without sL-selectin present. 
by demonstrating that the reactivity of anti-L-selectin mAb 
with L-selectin  § ceils could be inhibited by plasma. When 
lymphocytes were stained using anti-L-selectin mAb in un- 
diluted human plasma, no significant staining was obtained 
at concentrations of mAb that were saturating in RPMI/FCS 
(data not shown). Next, lymphocytes (1  ￿  106/100 #1) were 
incubated with various concentrations of L-selectin-directed 
mAb diluted  (1:100)  in  autologous  plasma or  autologous 
plasma which had been precleared of sL-selectin by immu- 
noprecipitation.  After completion of indirect immunofluo- 
rescence staining,  antibody binding  was assessed by flow 
cytometry. In most cases, the presence of plasma inhibited 
anti-L-selectin mAb staining when the mAbs were used at 
2  to 5  #g/ml  (Fig.  6).  Thus,  ,x,13-33  pM  IgG~  (150  kD) 
bound to "~21 pM sL-selectin (75 kD) based on the concen- 
tration of sL-selectin present in plasma (1.6/zg/ml) deter- 
mined as outlined above, sL-selectin-dependent inhibition of 
mAb binding was seen in plasma for mAb which recognize 
the lectin domain (anti-LAM1-3, -4, and -10) and the EGF- 
like domain (anti-LAM1-5, and -15).  In contrast, binding of 
the anti-LAMl-1 mAb, which binds an epitope in the EGF- 
like domain, was not significantly inhibited by the presence 
of plasma (Fig.  6 D). 
The LAMI-1 Epitope was not Detected on sL-selectin 
from Human Plasma 
Since anti-LAMl-1 mAb binding to lymphocytes was not in- 
hibited by plasma, the epitope identified by this mAb may 
not  be  present  on  sL-selectin.  To  examine  this  further, 
ELISA  were  performed  in  which  different  L-selectin-di- 
rected mAbs were bound to an ELISA plate as capture anti- 
bodies with the anti-LAM1-3 mAb as the detecting antibody. 
Lectin domain-specific antibodies (anti-LAM1-6, -7, -10, and 
-11) and EGF-like domain specific mAb (anti-LAM1-5 and 
-15) gave strong, easily detectable positive signals (Fig. 7). 
Wells  coated  with  the  anti-LAM1-3  and  -4  mAb,  which 
cross-block the  binding  of the  detecting  antibody  (anti- 
LAM1-3),  served  as  internal  controls  for background  re- 
activity. In contrast to all other mAb, anti-LAMl-1  gave a 
signal that was not significantly different from background, 
as defined by using BSA as the capture reagent.  Thus, the 
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Figure 6. The influence of sL- 
selectin on the binding of anti- 
L-selectin  mAb  to  lympho- 
cytes.  Heparinized  plasma 
was either  precleared  of sL- 
selectin using anti-LAM-Seph- 
arose or left on ice. Lympho- 
cytes  from  the  same  donor 
were resuspended in 100 #l of 
plasma (e) or predicated plas- 
ma (o). Various anti-L-selec- 
tin mAbs at different concen- 
trations  were  added  to  the 
plasma (1:100) and mAb bind- 
ing  was assessed  by indirect 
immunofluorescence staining. 
X~vhshed  lymphoeytes  were fixed 
in paraformaldehyde, and the 
intensity of fluorescence stain- 
ing  was  determined  by flow 
cytometry.  Values represent 
the relative mean intensity of 
fluorescence for stained ceils. 
These results are representa- 
tive of those obtained  in two 
sets of experiments. 
The Journal of Cell Biology, Volume 119, 1992  234 0.8 
0.6 
r~ 
O  0.4 
0.2 
0.0,~ 
￿9  "  ,"  '  "  "7  "T, 
..I  --I  --I  --I  --I  --I  ~  ~ 
￿9  =1  ..I 
CAPTURE  MONOCLONAL  ANTIBODY 
Figure 7. The epitope identified by the anti-LAMl-1 mAb is not de- 
tected on sL-selectin from plasma. Plasma was tested for detectable 
sL-selectin by a sandwich ELISA using the indicated anti-L-selec- 
tin mAb as catching antibody, and biotinylated anti-LAM1-3 mAb 
as detecting antibody. Anti-LAM1-3 mAb binding was visualized 
using  avidin-HRP  and  o-phenylenediamine  as  substrate.  BSA 
bound to the wells of the ELISA plate served as a control. Antibod- 
ies anti-LAM1-3 and -4 cross-block the binding of the detecting an- 
tibody (anti-LAMI-3).  Values represent mean 5: SD of OD values 
obtained in triplicate wells. These results are representative of  three 
similar experiments. 
epitope located  within the  EGF-like region which  is  spe- 
cifically recognized by the anti-LAMl-1 mAb appears to be 
lost from L-selectin upon shedding. As L-selectin was easily 
recognized by all L-selectin-specific mAb in immunofluo- 
rescence staining of lymphocytes and all three extracellular 
domains are preserved on sL-selectin found in plasma, con- 
formational changes in the L-selectin protein may lead to the 
loss of the EGF-like domain related LAMI-1 epitope. 
To determine whether the transmembrane or cytoplasmic 
regions of L-selectin are necessary to uphold the complete 
tertiary structure of its extraceUular domains, a second form 
of soluble L-selectin, a LAM-IgG fusion protein was gener- 
ated and epitope-mapped by ELISA. The chimeric eDNA 
used to generate the fusion protein was constructed so that 
it  contained  essentially  the  entire  extracellular  region  of 
L-selectin. Culture supernatant fluid of COS cells that were 
transiently transfected with the chimeric eDNA were tested 
for the production of LAM-IgG by ELISA. The anti-LAM1- 
5, -7, and -15 mAb, which detected sL-selectin in plasma and 
in supernatant fluid from PMA-stimulated K562-LAM cells, 
also bound the LAM-IgG chimera at similar levels (Fig. 8). 
In contrast, while the anti-LAMl-1 mAb failed to generate 
a significant signal with sL-selectin from plasma and K562- 
LAM transfectants,  it readily bound the LAM-IgG fusion 
protein (Fig. 8). Thus, it is likely that sL-selectin generated 
in vivo or in vitro loses a conformational determinant that 
is required for anti-LAMl-1  mAb binding. 
Discussion 
The presence of different isoforms of intact sL-selectin in 
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Figure 8.  Detection of the LAMI-1 epitope,  which is lost on sL- 
selectin  from plasma, on a  soluble LAM-IgG fusion protein.  A 
LAM-IgG chimeric eDNA was constructed and the fusion protein 
was expressed in COS cells. After 3 d of culture, supernatant fluids 
were  harvested  and  examined  for  LAM-IgG  (-)  content  by 
ELISA.  In parallel,  supernatant  fluid of PMA-stimulated  K562- 
LAM cells ([]) and plasma (diluted 1/5) ([]) were examined.  The 
indicated mAbs were bound to the wells of an ELISA plate and the 
ELISA was carried out as described  in Fig. 7. Bars denote mean 
OD values + SD of triplicate determinations. These results are rep- 
resentative of those obtained  in three separate experiments. 
plasma and  serum  was  revealed by Western blot analysis 
(Fig.  1).  sL-selectin in serum appeared to be derived from 
both lymphocytes and neutrophils since the analysis of sL- 
selectin  isolated  from neutrophils  (95-105  kD)  and  lym- 
phocytes (74 kd) produced bands of corresponding relative 
molecular mass. The differences in relative molecular mass 
between lymphocyte and neutrophil sL-selectin most likely 
result from differences in glycosylation of a  single protein 
species  since only a  single  L-selectin mRNA  species has 
been  identified  (33),  and K562  cells transfected with  the 
pLAM-1 eDNA that is complementary to this mRNA also 
produced  a  different  isoform  of sL-selectin.  Cleavage  of 
L-selectin is likely to be proximal to the membrane spanning 
region encoded by exon VHI; cleavage in this region would 
account for the small difference in relative molecular mass 
between the intact cellular L-selectin molecule and its shed 
form (23,  28, 40).  This is supported by the extraordinarily 
high degree of conservation of exon VIII between human 
L-selectin and the corresponding region of mouse L-selectin 
(9,  33).  In addition,  anti-L-selectin mAb binding  studies 
demonstrated that the lectin,  EGF-like, and SCR domains 
are retained by sL-selectin (Figs. 1 and 7). It is therefore pos- 
sible that the factor in rat lymph characterized by Chin and 
Woodruff as being capable of inhibiting lymphocyte attach- 
ment to HEV was in part sL-selectin (4-6). 
While the direct demonstration of sL-selectin in plasma 
and supernatant fluid from activated neutrophils and lympho- 
cytes confirms that the in vivo and in vitro loss of L-selectin 
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sL-selectin-ELISA allowed for the first time an easy, effi- 
cient, and sensitive method for quantification of sL-selectin. 
Remarkably, in a population of normal healthy blood donors 
the mean serum level of sL-selectin was determined to be 1.6 
•  0.8/~g/ml.  The concentration of sL-selectin was deter- 
mined by comparison with a reference plasma sample that 
had  been  standardized  by  two  independent  means,  and 
ranged between 0.85 and 1.9 #g/ml. The mean of this range 
of values of 1.3/~g/ml was therefore chosen as the basis of 
all calculations.  Experimental data derived from shedding 
experiments in K562-LAM transfectants further substantiate 
the validity of this estimate (44a). K562-LAM cells express 
30,000-43,000 L-selectin molecules on each cell as deter- 
mined  by Scatchard  analysis.  After PMA  stimulation  of 
these  cells,  all  L-selectin  molecules  (71  kD)  are  shed. 
Thereby, the concentration of sL-selectin in plasma can be 
calculated by comparing the concentration of sL-selectin in 
medium (13% the concentration of standard plasma) shed 
from K562 transfectants  (1  x  107 cells/ml) to a  titration 
curve of standard  plasma.  According  to this  calculation, 
plasma  concentrations  would lie  in  the  range  of 2.1-3.0 
#g/ml. Similar considerations make it highly unlikely that the 
amount of sL-selectin found in serum or plasma is generated 
from the shedding of cell surface L-selectin by blood leuko- 
cytes present during  the preparation  of the samples:  the 
quantity of sL-selectin actually found in serum is 10-25-fold 
higher than the quantity of L-selectin that could maximally 
be shed from the cell surface of leukocytes (~4 x  10~/ml) 
present  in  the  samples,  since  most  leukocytes  express 
50,000-100,000 receptors/cell as determined by Scatchard 
analysis (44a). Therefore,  sL-selectin must be generated by 
the ongoing shedding of cell surface L-selectin from leuko- 
cytes in vivo. 
Another adhesion molecule, ICAM-1, was recently shown 
to circulate in plasma at a concentration  of 0.16 #g/ml (35), 
a concentration 10-fold lower than that found for sL-selectin. 
Functional  activity of soluble ICAM-1, however, could only 
be demonstrated when it was immobilized to plastic (35). 
In contrast, sL-selectin semipurified  from plasma inhibited 
L-selectin-mediated lymphocyte attachment at suboptimal 
levels of ligand expression on TNF-activated  endothelium in 
a dose-dependent manner with complete inhibition at ,x,8-15 
#g/ml (Fig.  4). At concentrations  of sL-selectin similar to 
those found in the plasma of normal blood donors, a small 
but significant (p < 0.005) inhibition of leukocyte endothelial 
binding was observed at various levels of ligand expression 
(Fig. 5). Similarly, using a soluble fusion protein composed 
of the Fe portion of human IgG and the extracellular  domains 
of MEL-14 at 1 t~g per tissue section, Vvhtson  et al. (53) have 
found •75  % inhibition of lymphocyte binding to HEV. Pre- 
liminary  studies suggest that circulating  sL-selectin may be 
functional  in vivo since immunohistochemical  staining  of 
tissues  with  anti-L-selectin  mAb  revealed  sL-selectin 
specifically bound to the luminal surface of endothelial cells, 
both  on  HEV  endothelium  and  at  sites  of inflammation 
(Munro, M., B. Schleiffenbaum,  and T. E  Tedder,  manu- 
script in preparation).  This is not unexpected, as the MEL- 
14-IgG fusion protein also binds to HEV in vitro (53). 
High levels of relatively low avidity sL-selectin circulating 
in plasma might serve as a biological adhesion buffer system 
to prevent the attachment of leukocytes at sites where low 
level upregulation  of the L-selectin ligand has occurred on 
endothelial cells, similar to the function proposed for soluble 
P-selectin (12). This hypothesis is in keeping with the small 
but consistent inhibitory effect of physiological  concentra- 
tions of sL-selectin on L-selectin specific lymphocyte attach- 
ment to HUVEC during the course of ligand induction (Fig. 
5). The inhibitory effect of sL-selectin may be biologically 
most  relevant  at  low levels of ligand  expression.  Future 
studies  on  the  binding  affinity  of sL-selectin  for  its  en- 
dothelial  ligand  will have to be carried out to determine 
whether sL-selectin can efficiently compete with cell-bound 
receptor for ligand.  Since the number of sL-selectin mole- 
cules in blood is much higher than the number of cell-surface 
receptors in the same volume of blood, it is likely that sL- 
selectin  is of a lower affinity. Alternatively,  their affinities 
may be equivalent,  but cell-surface receptors may function 
in a cooperative manner or the localized relative density of 
receptors on the ceil surface may be higher than the corre- 
sponding relative density in solution.  It is also possible that 
the increase in affinity of L-selectin which follows cellular 
activation  may allow  the competitive displacement of sL- 
selectin from the endothelial  surface (41). 
An interesting finding was that sL-selectin did not contain 
the epitope wihhin the EGF-like domain identified  by the 
anti-LAMl-1 mAb, while this epitope was readily demon- 
strated on the LAM-IgG fusion protein (Fig. 8) and is found 
on cell-surface L-selectin (21, 42,  51). This was revealed 
both by ELISA (Fig. 7) and by a lack of competitive inhibi- 
tion in immunofluorescence  staining of leukocytes (Fig. 6). 
Since the EGF-like domain is retained in sL-selectin, altera- 
t_ions in the tertiary structure of L-selectin may have occurred 
after shedding  that result in a  lack of anti-LAMl-1  mAb 
binding. It is possible that the Fc portion of IgG fused to the 
L-selectin extracellular  domain was sufficient to stabilize the 
tertiary structure of L-selectin, so that anti-LAMlq mAb is 
still able to recognize its epitope on this soluble form of the 
molecule. Anti-LAMI-1 mAb binding to L-selectin not only 
inhibits  leukocyte attachment to endothelium, but also in- 
duces an increase in the binding of PPME and fucoidin (21, 
42),  carbohydrates which define  L-selectin lectin activity 
(16, 21, 43, 47, 56, 57). Since conformationai  changes involv- 
ing the LAMlq epitope may be important for the increase 
in L-selectin affinity that follows leukocyte activation  (41), 
it is conceivable that the loss of the LAMI-1 epitope results 
in a lower affinity of sL-selectin for ligand. 
The levels of sL-selectin normally found in human serum 
competitively inhibited  the in vitro binding  of L-selectin- 
directed mAbs to leukocytes. This finding has important im- 
plications  for future in vivo studies both in animals and hu- 
mans.  Functionally active mAbs will have to be introduced 
into animals  in large enough quantities  to saturate  binding 
to sL-selectin in blood to allow efficient binding  of mAb to 
leukocytes and subsequent modulation of leukocyte func- 
tion.  In addition, the formation  of immune complexes be- 
tween sL-selectin and L-selectin directed mAb will have to 
be considered.  The use of F(ab): or F(ab) fragments in- 
stead of whole immunoglobulin  might also be preferable, es- 
pecially  when  neutrophil  functions  are  to  be evaluated. 
Therefore,  inhibitory  mAb  such  as  anti-LAMl-1  which 
recognizes epitopes on L-selectin that are lost on sL-selectin 
might also prove helpful. 
It has been proposed that L-selectin shedding is necessary 
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lowing rapid deadhesion of the leukocytes from endothelial 
cell  surfaces.  However,  immunohistochemical  staining  of 
lymph  nodes  and  inflamed  tissues  demonstrated  variable 
proportions of L-selectin  + extravascular  lymphocytes,  neu- 
trophils,  and monocytes  (Munro,  M.,  B.  Schleiffenbaum, 
and T. E  Tedder,  manuscript in preparation).  Therefore, it 
is possible that once leukocytes localize in tissues, they con- 
tinue to express L-selectin, but this receptor is continually 
shed. As only a small proportion of the body's leukocytes are 
normally found in the circulation, it might be hypothesized 
that tissue localized leukocytes represent a major source of 
sL-selectin.  The in situ production of sL-selectin by tissue- 
localized leukocytes would help explain the unpredicted high 
level of sL-selectin found in the circulation.  However, the 
L-selectin  ligand  expressed  by  HEV  of peripheral  lymph 
nodes is shed in vitro and may also be shed in vivo (28). 
Thereby,  if the ligand is shed at high enough levels in vivo, 
it might adhere to sL-selectin,  thus  inhibiting its ability to 
affect cell adhesion in vivo. In addition, significant levels of 
the shed ligand may also serve as an inhibitor of L-selectin- 
mediated adhesion to endothelium.  Nonetheless,  the pres- 
ence of a soluble isoform of L-selectin with functional activ- 
ity in serum indicates a new potential mechanism for in vivo 
regulation of leukocyte attachment  to endothelium. 
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